To view this email as a web page, click here

Today's Rundown

Featured Story

Vir, GSK unveil final data for COVID-19 antibody en route to 2021 filing

With final phase 3 data in hand, Vir Biotechnology and GlaxoSmithKline are seeking full approval for their COVID-19 antibody by the end of the year. The study found that the treatment, sotrovimab, slashed hospitalizations and deaths by 79% in adults with mild to moderate COVID-19 who were at high risk of their disease becoming severe.

read more

Top Stories

Allogene, Overland's new China cell therapy JV biotech nabs WuXi CSO Yao as new CEO

WuXi veteran Shuyuan Yao, Ph.D., is stepping down from the Chinese R&D giant to lead the new joint venture, Allogene Overland Biopharm.

read more

Arrowhead can see the Horizon with $700M biobucks pact for an early RNA gout med

Arrowhead Pharmaceuticals will bring an RNA interference therapeutic through preclinical stages and Horizon will handle clinical development and commercialization for the potential gout treatment.

read more

Sponsored: Addressing Roadblocks in Decentralized Clinical Trials

In a recent virtual roundtable discussion, industry experts shared their insight on the challenges faced in implementing decentralized trials and how to address them.

read more

After seeing its GSK-backed trial ditched, LAG-3-focused Immutep secures cash, plots new trial push

Australian biotech Immutep has secured $60 million Australian dollars through a “two-tranche institutional placement” as it eyes a deeper push into the clinic and looks to raise a further AU$5 million via a share purchase plan.

read more

Sponsored: Culture Drives Employee Engagement, Supports Business Growth

By refocusing company culture around the connection between employees and the rare disease community, Alexion has increased employee engagement and charted a new path for business success. Read more.

read more

Tarsus posts positive results on eyedrop treatment for eyelid mange, expects to file for FDA approval next year

Tarsus Pharmaceuticals met all primary and secondary endpoints in a pivotal phase 2b/3 trial of its eyedrop treatment for eyelid mange, and expects to file for regulatory approval next year following results of another pivotal study already underway.

read more

Roche's Alzheimer's antibody lowers biomarkers in inherited form of disease, though impact on symptoms is unclear

Experimental anti-amyloid antibodies from Eli Lilly and Roche failed to improve symptoms of Alzheimer’s disease in a phase 2/3 study, but analysis of the the trial continued. Now, the investigators at Washington University are extending the trial of Roche’s drug based on findings suggesting it may help a subset of patients.

read more

The top 10 ESG pharma companies in 2021

Environmental, Social and Governance (ESG) is the new corporate sustainability yardstick. And investors are pushing ESG accountability—thanks in part to the pandemic—to the front page across industries, including pharma.

read more

Resources

Whitepaper: How to Launch a Successful BYOD Strategy in Any Phase

For faster deployment, improved patient engagement, and better-quality data — go where your patients are. GO BYOD with Lunexis™ from Clinical Ink.

Paid Marketplace: Story of Success: Ashfield Healthcare Empowers Field Sales to Grow Market Share based on Data

Discover how Ashfield Healthcare uses the power of data and analytics to enable pre-call planning, inform sales rep actions and drive higher market share for its target pharmaceutical products.

eBook: Improving Diversity and Inclusion in Clinical Trials

Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them.

Whitepaper: Closed Cell Processing System Benefits for Cell & Gene Therapy

Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process.

Guide: Your Guide to Overcome Inconsistent Clinical Data Standards

Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Content Hub: Process Intensification Resource Center

A one-stop hub for Cytiva resources to support process intesification

Content Hub: Emerging Biotech Resource Center

A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule

Content Hub: Remarque Systems Resource Hub

Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. 

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Whitepaper: Achieving a Successful Drug Product Technology Transfer

Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.

Events